Pegcrisantaspase
- Generic Name
- Pegcrisantaspase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1448590-54-2
- Unique Ingredient Identifier
- Y8KTZ6Y35U
- Background
Pegcrisantaspase is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Conditions
- Interventions
- Procedure: Biospecimen CollectionRadiation: 3-Dimensional Conformal Radiation TherapyBiological: BlinatumomabProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: DexamethasoneDrug: Calaspargase PegolDrug: Hydrocortisone Sodium SuccinateProcedure: Lumbar PunctureDrug: MethotrexateBiological: NivolumabDrug: MercaptopurineDrug: PegaspargaseDrug: PegcrisantaspaseDrug: Vincristine Sulfate
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 300
- Registration Number
- NCT04546399
- Locations
- ๐บ๐ธ
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
๐บ๐ธCorewell Health Dearborn Hospital, Dearborn, Michigan, United States
๐บ๐ธCorewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids, Michigan, United States
Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
- Conditions
- Recurrent T-Cell Prolymphocytic LeukemiaRecurrent Acute Biphenotypic LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Acute Biphenotypic LeukemiaRefractory T-Cell Prolymphocytic LeukemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT04526795
- Locations
- ๐บ๐ธ
M D Anderson Cancer Center, Houston, Texas, United States
A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02257684
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
๐บ๐ธArkansas Children's Hospital, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.